United States - English - NLM (National Library of Medicine)

a-s medication solutions - tretinoin (unii: 5688utc01r) (tretinoin - unii:5688utc01r) - tretinoin 0.25 mg in 1 g - tretinoin cream, usp is indicated for topical application in the treatment of acne vulgaris. the safety and efficacy of this product in the treatment of other disorders have not been established. the product should not be used if there is hypersensitivity to any of the ingredients.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - isotretinoin, quantity: 10 mg - capsule, soft - excipient ingredients: soya oil; yellow beeswax; hydrogenated soya oil; partially hydrogenated soya oil; gelatin; glycerol; titanium dioxide; iron oxide red; iron oxide yellow; propylene glycol; brilliant blue fcf; ethanol; purified water; shellac; strong ammonia solution - treatment of severe cystic acne. a single course of therapy has been shown to result in complete and prolonged remission of disease in many patients. if a second course of therapy is needed, it should not be initiated until at least eight weeks after completion of the first course, since experience has shown that patients may continue to improve while off the drug. because of significant adverse effects associated with its use, isotretinoin should be reserved for patients with severe cystic acne who are unresponsive to conventional therapy, including systemic antibiotics.

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - tretinoin (unii: 5688utc01r) (tretinoin - unii:5688utc01r) - tretinoin gel and cream are indicated for topical application in the treatment of acne vulgaris. the safety and efficacy of the long-term use of this product in the treatment of other disorders have not been established. use of the product should be discontinued if hypersensitivity to any of the ingredients is noted.

United States - English - NLM (National Library of Medicine)

oceanside pharmaceuticals - tretinoin (unii: 5688utc01r) (tretinoin - unii:5688utc01r) - tretinoin 0.5 mg in 1 g

United States - English - NLM (National Library of Medicine)

avera mckennan hospital - tretinoin (unii: 5688utc01r) (tretinoin - unii:5688utc01r) - tretinoin 10 mg

United States - English - NLM (National Library of Medicine)

rebel distributors corp - tretinoin (unii: 5688utc01r) (tretinoin - unii:5688utc01r) - tretinoin is indicated for topical application in the treatment of acne vulgaris. the safety and efficacy of the long-term use of this product in the treatment of other disorders have not been established. use of the product should be discontinued if hypersensitivity to any of the ingredients is noted.

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - tretinoin (unii: 5688utc01r) (tretinoin - unii:5688utc01r) - tretinoin is indicated for topical application in the treatment of acne vulgaris. the safety and efficacy of the long-term use of this product in the treatment of other disorders have not been established. use of the product should be discontinued if hypersensitivity to any of the ingredients is noted.

United States - English - NLM (National Library of Medicine)

oceanside pharmaceuticals - tretinoin (unii: 5688utc01r) (tretinoin - unii:5688utc01r) - tretinoin gel is indicated for topical treatment of acne vulgaris. none. pregnancy category c there are no well-controlled trials in pregnant women treated with tretinoin gel. tretinoin gel should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. tretinoin gel at doses of 0.1, 0.3 and 1 g/kg/day was tested for maternal and developmental toxicity in pregnant sprague-dawley rats by dermal application. the dose of 1 g/kg/day was approximately 4 times the clinical dose assuming 100% absorption and based on body surface area comparison. possible tretinoin-associated teratogenic effects (craniofacial abnormalities (hydrocephaly), asymmetrical thyroids, variations in ossification, and increased supernumerary ribs) were noted in the fetuses of tretinoin gel treated animals. these findings were not observed in control animals. other maternal and reproductive parameters in the tretinoin gel treated animals were not different from control. for purposes of comparison of the

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - tretinoin (unii: 5688utc01r) (tretinoin - unii:5688utc01r) - tretinoin gel is indicated for topical treatment of acne vulgaris. none. there are no well-controlled studies in pregnant women treated with tretinoin gel. tretinoin gel should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. tretinoin gel at doses of 0.1, 0.3 and 1 g/kg/day was tested for maternal and developmental toxicity in pregnant sprague-dawley rats by dermal application. the dose of 1 g/kg/day was approximately 4 times the clinical dose assuming 100% absorption and based on body surface area comparison. possible tretinoin-associated teratogenic effects (craniofacial abnormalities (hydrocephaly), asymmetrical thyroids, variations in ossification, and increased supernumerary ribs) were noted in the fetuses of tretinoin gel treated animals. these findings were not observed in control animals. other maternal and reproductive parameters in the tretinoin gel treated animals were not different from control. for purposes of comparison of the animal exposure to

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - tretinoin (unii: 5688utc01r) (tretinoin - unii:5688utc01r) - tretinoin capsules are indicated for the induction of remission in patients with acute promyelocytic leukemia (apl), french-american-british (fab) classification m3 (including the m3 variant), characterized by the presence of the t(15;17) translocation and/or the presence of the pml/rarα gene who are refractory to, or who have relapsed from, anthracycline chemotherapy, or for whom anthracycline based chemotherapy is contraindicated. tretinoin is for the induction of remission only. the optimal consolidation or maintenance regimens have not been defined, but all patients should receive an accepted form of remission consolidation and/or maintenance therapy for apl after completion of induction therapy with tretinoin. tretinoin is contraindicated in patients with a known hypersensitivity to tretinoin, any of its components, or other retinoids.